BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its earnings results on Monday. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06, Briefing.com reports. The company had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. BioCryst Pharmaceuticals’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.28) earnings per share.

BioCryst Pharmaceuticals Stock Up 18.4 %

Shares of NASDAQ:BCRX opened at $5.27 on Tuesday. The firm has a 50 day moving average of $4.92 and a 200 day moving average of $5.46. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.47 and a beta of 1.96. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.96.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BCRX. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $13.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.